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HIV-1 Protease Inhibitors From Marine Brown Alga: A 
Literature Review 
 
Abstract 
The human immunodeficiency virus type 1 (HIV-1) causes an infectious 
disease that if left untreated can progress to acquired immunodeficiency 
syndrome (AIDS) and be fatal. Finding a cure and more treatments for HIV 
has become a top priority in medical research, and due to the cost of 
synthetic HIV medication, finding a low-cost alternative is essential.  
Marine pharmacology has provided a possible solution to costly HIV 
medication through compounds derived from marine brown algae that 
inhibit the HIV-1 protease (PR).  The objective of this study is to emphasize 
the necessity for further research in HIV-1 protease inhibition using marine-
wildlife-derived compounds.  In order to better understand the process of 
protease inhibitors, I will investigate the process of producing and purifying 
HIV-1 PR, extracting and isolating brown algal compounds, and the assays 
used to test the inhibition effects of the brown alga compounds.  This study 
demonstrates the potential of marine pharmacology as an inexpensive 
alternative to synthetic pharmaceuticals for HIV-1 PR inhibition. 
 
I. Introduction: 
The HIV-1 is a viral infection that can be transmitted through direct 
exposure to infected bodily fluids.  Global HIV and AIDS statistics indicate 
HIV has infected about 38.1 million people, with 36.9 million people and 
2.6 million children seeking treatment.  If HIV is left untreated, the virus 
can cause acquired immune deficiency syndrome (AIDS), which has caused 
about 25.8 million deaths due to AIDS-related illnesses. [6] HIV/AIDS is an 
illness people must live with for the rest of their lives. However, the 
medication to keep people healthy is quite expensive. [18] This makes a cure 
for HIV desirable, and researchers have been struggling to find a quick 
solution to prevent this virus from full maturation.   
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Figure 1: This diagram depicts the process in which a healthy CD4 T Cell is infected by 
HIV-1 and then used as a viral host to produce mature HIV-1 virions. 
(IMG: https://cooljargon.com/ebooks/biology/m44599/index.cnxml.html) 
 
The process in which an HIV-1 virion infects its host, the CD4 T Cell, is 
through seven steps depicted by Figure 1. First, the virion must fuse to the 
cell membrane of the CD4 cell through the CD4 binding site—illustrated as 
4 yellow circles on the CD4 cell—where the co-receptor will help fuse the 
viral membrane to the CD4 cell membrane.  Once attached to the 
membrane, the HIV proteases (PR) within the virion cleaves the Gag and 
Gag-Pro-Pol polyproteins into the following matrix (MA), capsid (CA), 
nucleocapsid (NC), and P6.  The PR is also responsible for cleaving 
enzymes such as more proteases (PR), reverse transcriptase (RT), reverse 
transcriptase-RNase (RT-RH), and integrase (IN).  The proper cleavage of 
these polyproteins is essential for the maturation of a virion. [10][9] Then, the 
PRs break away the capsid to expose the viral RNA, where reverse 
transcriptase will construct viral DNA, which integrase will insert into the 
host DNA.  This results in a mutation in a CD4 cell that helps replicate viral 
proteins and RNA.  This new viral RNA is transported to the walls of the 
CD4 cell by viral proteins in order to start the production of new, mature 
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HIV-1 virions that are released after maturation.  This is where the CD4 
host cell dies due to the crowding of the cell with virions, causing the cell 
to rupture and release large amounts of mature virions. 
 
This process has allowed researchers to create preventative treatment and 
lifelong treatment for those already infected.  The understanding of the 
mechanisms of HIV-1 infection has contributed to research in order to one 
day create a vaccine for HIV.[25][4] In Figure 2, the current inhibitors in 
treatment are indicated in red text, along with additional vocabulary 
necessary for understanding the structure of the HIV-1 virion.  The target 
for most medication for HIV-1 is PR inhibitors, since inhibiting the protease 
will prevent virions from reaching maturation before infecting the host cell.  
Other inhibitors can target the entry of the virion by inhibiting the virus-cell 
membrane fusion. [23] 
 
 
 
Figure 2: HIV-1 virion diagram depicting all essential components for infection of CD4 T 
Cell host (left). The inhibition of these components is essential in creating treatment and 
potentially a cure for HIV-1 (right).  
(IMG: http://www.forbes.com/sites/quora/2016/09/29/these-two-promising-treatments-
could-change-the-fight-against-hiv/#5f2ca215537b). 
 
In this review, I will investigate the natural marine products used in HIV-1 
PR inhibition in order to review the current understanding of how natural 
products are used in pharmaceuticals.  I will look into the host system 
selection process, the production of PR, the isolation and characterization 
of PR from host cells, the extraction of bioactive chemicals from marine 
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plants, and the testing of the marine plant natural products HIV-PR 
inhibiting effects.  This article will illuminate the interdisciplinary 
cooperation between biochemical engineering and natural product research 
to help provide a better understanding of current biotechnology for large-
scale viral protease production and strengthen the knowledge known about 
marine-plant-derived pharmaceuticals. 
 
II. HIV-1 PR production from bacterial vectors 
The production of the PR is a long and tedious process that can sometimes 
yield little to no PR if using the wrong host cell body or other conditions 
are not met.  The organisms available for protein synthesis that are readily 
available consist of bacteria, yeast, filamentous fungi, and unicellular. [21] 
However, for this particular peptidase, the E. coli host system has been well 
documented and continues to show results in the literature.  This section 
will review the production of viral protease from literature and look into the 
process of producing PR. 
 
Production of PR from E. coli is a reoccurring theme in most literature on 
producing HIV-1 PR in recent years, and in this process the type of PR is 
selected based on the compatibility of the strain of E. coli to optimize the 
yield of HIV-1 PR. [5] For example, Nguyen et al. used a gene sequence 
cloned from a Vietnamese HIV-1-infected patient to obtain a native HIV-1 
protease gene. The HIV-1 PR gene then had to be amplified and ligated 
using polymerase chain reaction (PCR).  This process makes sure the gene 
of interest is amplified and isolated.  In this scenario, the PR gene is located 
in between the Gag and Pro gene.  The PCR process removes Gag and Pro 
genes and amplifies the desired gene by using digestive enzymes that cleave 
these unwanted genes.  The gene had to be modified to make purification 
much simpler by adding a 6X His tag to the C-terminus and had to be 
encoded with an auto cleavage site at the N-terminus using designed 
primers.  Then, it was cloned into a pET32a (+) plasmid containing the HIV-
1 protease-encoding sequence along with sequences encoding an auto 
cleavage site GTVSFNF at the N-terminus.  The plasmid also contained a 
TEV plus 6× His tag at the C-terminus and was expressed using Escherichia 
coli BL21 DE3 strain as the host cell for the expression of this PR.  Nguyen 
had 9 plasmids from which only the highest expressed plasmid was selected 
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for the E. coli transformation.  Through this process, Nguyen et al. 
expressed about 4 mg of protein per liter of cell culture.  This article 
provides strong evidence that production of the HIV-1 PR is expressed and 
cultured in the E. coli bacterial host system. 
 
The process detailed by Nguyen et al. shows the possibility of obtaining this 
PR using E. coli, and this creates room for optimization of this process.  
Bashiri et al. indicates that the E. coli BL21 DE3 strain is problematic due 
to the leakage of expression in lac promoter and T7-based systems.  He 
suggests that the BL21-AI strain might lead to tighter regulation in 
expression and using a rhaBAD promoter to increase protein accumulation, 
protein solubility, and cell fitness.  As for affinity tagging, the 6XHis tag 
used in Nguyen’s experiment can be replaced with fusion partners, which 
consist of fusion proteins that reduce cost in purification of PR and increase 
the yield of PR produced. [3][21] 
 
III. Purification and characterization of HIV-1 PR 
This section will cover the purification process and will investigate current 
techniques used for characterization of the HIV-1 viral protease.  Affinity 
column chromatography is a process in which proteins—which are removed 
from their host cells using lysis buffer to break the cell walls—are isolated 
from undesired compounds and contaminant proteins using high affinity 
resin beads in a column.  This process consists of pumps that contain an 
elution and binding buffer, resin beads that bind to the 6XHis tag on the 
desired protein, and collection tubes to collect the desired protein.  These 
components can all be found in a Fast Protein Liquid Chromatography 
(FPLC) instrument which monitors the compounds in the lysed and 
suspended cell pellet using a UV detector or specified light detector that can 
detect when a protein of a given or desired wavelength is being eluted from 
the column.  Maseko and Nguyen both used column chromatography for 
purification and sodium dodecyl sulfate polyacrylamide gel electrophoresis 
for characterization of their proteases.  This section will highlight both 
processes, along with current techniques that can strengthen their results. 
 
Purifying PR using affinity column chromatography is a common technique 
used in the isolation of proteins from contaminants. Maseko et al. used a Q 
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Sepharose Fast Flow anion exchange (QFF) and GSTrap column 
chromatography.  QFF columns bind to charged biomolecules, in this case, 
the HIV-1 PR and other charged proteins.  This is why there is another 
column GSTrap that binds specifically to the glutathione S-Transferase 
(GST) tagged proteins. [14] Maseko used a different plasmid with his GST 
tag based on his HIV-1 PR.  The last affinity column selectively isolated 
only proteins with the tag, which yields a higher purity in his final product.  
Nguyen et al. used a 2 Tandem QFF similar to what Maseko used in order 
to isolate all charged biomolecules. However, Nguyen then used a Ni-
Sepharose column in order to isolate her HIV-1 PR with a 6XHis tag.[16] 
The purification step of this PR demonstrates the importance of purification 
tags and purity in the final product.  The two column steps help reduce the 
contamination in the PR final samples and help in concentrating the final 
product. 
 
Characterization of PR using SDS PAGE and mass spectrometry is a 
common process for quickly analyzing the PR, the quickest being SDS-
PAGE.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-
PAGE is a common procedure, where protein samples are characterized 
based on the size of the protein.  The accuracy of this process can be 
intensified if the size of the protein is known.  Maseko et al. detail the PR 
sizes for his experiment by comparing his two PR variants with his control 
wildtype PR, which are 11.5, 11.6 and 11.7 kDa. [14] However, Nguyen et 
al. was only interested in the single band of approximately 13 kDa since she 
was not testing inhibition effects on other HIV-1 PR variants.[16] The most 
accurate method to characterize a protein is through mass spectrometry, 
which is the detection of mass isotopes of a given molecule.  The purity of 
the sample and control is paramount to getting the best results.  The process 
of obtaining a mass spectra of a sample is long and tedious, consisting of 
method development and experiment runs that can take hours to process.  
Loo et al. [12] demonstrate a mass spectra of the HIV-1 PR used in the 
experiment, where they detail the procedure of how they obtained their data 
(Figure 3).  This procedure is essential in priming the mass spectrometer 
and prepping the PR samples. 
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Figure 3: This image depicts the HIV-1 PR mass spectra, where you can note the isotropic 
resolution of this M+12H ion. [12] 
 
IV. Marine plant natural product extraction from marine wild life with 
potential anti-HIV properties 
In the discovery of new pharmaceutical or nutraceutical compounds, these 
compounds must be either synthesized in a laboratory or extracted from the 
natural source.  This section will look into the extraction of natural 
compounds from marine wildlife, and in particular, plants and algae that 
have pharmaceutical applications such as; antioxidants, anti-inflammatory, 
anti-viral/retroviral, and anti-fungal.[15][22]  This scale of extraction for 
pharmaceutical purposes would need to be conducted on a much larger scale 
if it were to be used for drug discovery research.  Malve speaks of marine 
pharmacology as a viable source for alternative drug discovery for new 
illnesses emerging from marine microbes, which in this section pertains to 
marine alga. [13][7] Uzaira et al. indicate that microorganisms like alga have 
exhibited in-vitro inhibition of HIV-1 replication cell lines. [27][19] It is 
through marine organisms that most of the answers to infectious diseases 
can be found. However, there is still more research needed in this field to 
identify and isolate these compounds; Figure 4 illustrates the process and 
ways that these compounds are characterized. 
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Figure 4: This picture illustrates the process of extracting, isolating and testing marine 
pharmaceuticals using characterization instrumentation like high performance liquid 
chromatography and mass spectrometry. 
(IMG: https://npsg.ncifcrf.gov/DISCOVER.JPG) 
 
Potential viral protease inhibitors are found in algal natural products in the 
pacific coast of Japan and South Korea called Ecklonia cava.  This brown, 
edible algae consists of phlorotannins; some are Eckol, 6, 6’-Dieckol, 8, 4”-
Dieckol and 8, 8’- Bieckol.  In particular, 8,8’-Dieckol is known to inhibit 
the protease more than all of the other derivatives because the inhibiting 
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effects on PR are greater than the other 3 phlorotannins, PR-IC50 81.5±9.6 
µM.1.  This indicates that this algal derivative should be further investigated 
to determine whether it can be used for PR inhibition.  Artan et al. mentions 
that 8, 8’-bieckol has a much higher inhibiting effect. [2] In this experiment, 
the extraction and isolation of 8, 8’-bieckol from Ecklonia cava is run by 
washing E. cava with water three times followed by drying 1 kg of the 
washed sample at 60℃ for 12 hours. Following that, the dried sample is 
ground and then extracted with methanol (3x). This methanol extract is then 
dissolved in water and partitioned with n-hexane, which results in an 
aqueous layer that is partitioned with ethyl acetate.  The organic solvent 
fraction is concentrated in vacuo and divided into ten fractions on a silica 
gel column chromatography (Merck, 230—400 mesh, 300 g) using 
trichloromethane-ethyl acetate-methanol mixtures of 50 : 2 : 1 (f. 1), 25 : 5 
: 1 (f. 2, f. 3), 10 : 5 : 1 (f. 4—f. 6), 5 : 5 : 1 (f. 7, f. 8), 100% MeOH (f. 9, f. 
10); 1 l each.[2]  The desired compound is obtained from fraction 5 through 
recrystallization in methanol/water.  The information regarding the method 
for extracting this compound is essential in order to purify the compound 
out of E. cava.  This compound can also be bought from 3B Scientific 
Corporation (3BSC SKU# PL074128). 
 
V. HIV-1/2 PR inhibition analysis 
Finding the right assay to quantify the results in inhibitor experiments can 
be tricky due to the desired conditions of the PR and marine natural product 
optimal conditions differing.  Furthermore, determining the type and how 
much the natural product is inhibiting takes time, and sometimes the current 
method used is not the most accurate.  This is where technology is involved 
and can determine whether an experiment is reliable based on the instrument 
used.  In this section I will go over two assays: one that used high 
performance liquid chromatography (HPLC) to determine the inhibition 
effects and the fluorescence resonance energy transfer (FRET) assay that is 
commercially used in the pharmaceutical industry.  FRET is measuring the 
amount of a particular compound given a specific wavelength that the 
compound can be detected in. 
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Figure 5: Process flow diagram of an HPLC and the components it has. 
(IMG: http://www.waters.com/waters/en_US/How-Does-High-Performance-Liquid-
Chromatography-Work%3F/nav.htm?cid=10049055&locale=en_US) 
 
The HIV-1 protease assay using HPLC: HPLC is an instrument used to 
measure the amount of compounds within a solution using a column that 
separates each compound; these compounds go through a specific 
wavelength, where they can be detected and quantified (shown in Figure 
5).  Ahn et al. used HPLC to determine the amount of hydrolysate and 
remaining substrate from her inhibitor reaction, where the HIV-1 PR 
cleaves this substrate and the products are hydrolysate.  The following 
conditions were set for this experiment: column, Inertsil ODS-3 (4.63150 
mm, GL Sciences Inc., Japan); elution, a linear gradient of CH3CN 
(15→40%) in 0.1% TFA; injection volume, 20 ml; flow rate, 1.0 ml/min; 
and detection, 280 nm. The retention time for hydrolysate and substrate to 
be eluted is at 8.61 and 10.84 min, respectively.  To determine the inhibition 
activity of the compound in PR, reaction was calculated using this equation: 
% inhibition = 100X (Acontrol-Asample)/ (Acontrol), where A is a relative 
peak area of the hydrolysate; Acetyl pepstatin (Bachem AG) was used as a 
positive control in this assay. [1]  
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Figure 6: This diagram illustrates how the FRET assay works and the proper way of 
running controls and experimental trials. (A) This substrate fluoresces at an excitation of 
475nm and an emission at 610nm, where if there is activity the substrate will not fluoresce.  
(B) The substrate (GCC) was tested by itself, substrate + protease, substrate + inhibitor 
(Ritonavir) and substrate + inhibitor + protease. [8] 
 
The HIV-1 PR activity can also be analyzed using the fluorescence 
resonance energy transfer (FRET) assay specifically meant for testing HIV-
1 PR inhibition compounds.  The FRET HIV-1 PR assay works by using a 
substrate that fluoresces at a given excitation and emission wavelength.  
HIV-1 PR is determined to be active if there is no fluorescence, since the 
whole substrate must be intact to fluoresce.  This FRET assay is used in 
industries to screen several HIV-1 PR inhibitors and is commercialized, 
making this a readily available option when screening for HIV-1 PR 
inhibitors.[8][29]  This method is more preferable than HPLC since running 
HPLC can be costly and takes more time to run effectively.  The accuracy 
of a HPLC is what makes the HPLC method desirable; with FRET, the 
accuracy is more of a quick way to screen through several inhibitors.  This 
is why using both would be beneficial by using FRET assay to screen 
through several marine natural PR inhibitors and then run a HPLC assay for 
the inhibitors that made it past the screening.  
 
VI. Discussion 
The literature in this review contributes a foundation to marine 
pharmacology and HIV-1 research.  Nguyen’s contribution to HIV-1 PR 
expression and production allows for reproducing the same method for 
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future experiments like HIV-1 PR inhibitor simulations that are crucial in 
understanding the structural change of a PR when present with an inhibitor 
and catalytic response after HIV-1 RNA direct interaction.[19][17][20] Maseko 
and Nguyen both provide sufficient information to optimize current HIV-1 
PR purification processes, suggesting new forms of purification like fusion 
protein tags, using different plasmids with better binding affinity for column 
chromatography.[24] Artan provides an extraction process that can be used 
to extract other algal natural products that have been used by other marine 
pharmacology researchers.[26][28] Additionally, HIV-1 PR assays have been 
created by researchers like Ahn’s HPLC assay and Zhu’s FRET assay; this 
creates a platform for testing inhibitors at a small to large scale.  These 
contributions are what establish potential drug components in HIV-1 PR 
medication.  These contributions to marine pharmacology and HIV-1 
research are just the building blocks for new and improved processes for 
nutraceuticals. 
 
The strengths and weaknesses of the literature can be addressed through 
further research in each process.  The expression and production of HIV-1 
PR can always be optimized through further investigation in plasmids with 
better binding affinity tags and designing primers that can amplify the PR 
gene more efficiently.  The selection of better E. coli strains through large 
scale screening of different strains that do not have the leakage problems 
like T-7 and lac promoter strains. This can be addressed by screening 
through strains with a rhaBAD promoter to increase protein accumulation, 
protein solubility, and cell fitness.  Purification and characterization of HIV-
1 PR can be optimized by replacing affinity tags with fusion protein that can 
significantly reduce cost, and using SDS-PAGE and mass spectrometry 
together to characterize PR will only strengthen the literature.  Extraction 
and isolation of marine plant natural products can be optimized by using 
industry-grade plant extracting units to provide for better purity and 
additional controls for conditions specific to each compound.  The HIV-1 
PR assay development has been optimized through FRET and HPLC 
methods that detail the processes and controls using reliable instrumentation 
that are standard in research. The next steps in HIV-1 PR protease inhibitor 
research would be to further investigate other marine organisms and test 
their inhibitor activity of HIV-1 PR. 
13
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